Advances in biotechnology have driven the development of vaccines beyond traditional inactivated whole cell organisms into novel protein polysaccharide conjugates, peptides, and recombinant proteins. This unconventional drug class, however, comes with its own set of challenges. Its sheer diversity requires a custom approach to safety assessment that considers the compound’s unique characteristics, manufacturing process, and indications.

In this webinar, you’ll learn how to design appropriate toxicity tests for vaccines and new adjuvants and how to determine most relevant animal models for your vaccine’s safety program.


  • Benoît Ruot, PhD, MSc, Director, Scientific Advisory Services Europe, Charles River